Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026986 (myelodysplastic syndrome)
 14,926 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Early identification and treatment of depression can prevent the development of the full depressive episode and its consequences. Although the Beck Depression Inventory-II is among the most widely used tools for measuring depression, there are relatively few studies that empirically confirm any cutoff points for screening depression among university students. Our subjects were 400 students from Ilam University (Iran). On the basis of a diagnostic interview checklist, the subjects were differentiated whether they were major depressive syndrome positive (MDS+) (i.e., fulfill criteria A and C of major depressive episode Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria) or significant depression positive (SD+) (having depressed mood or anhedonia that caused significant distress or dysfunction). According to receiver operating characteristic curves obtained, the cutoff point of 22 or greater was the most suitable to screen MDS, whereas for screening milder but clinically significant depression (i.e., having depressed mood or anhedonia that caused significant distress or dysfunction), the cutoff point of 14 or greater was the best.
...
PMID:Using the Persian-language version of the Beck Depression Inventory-II (BDI-II-Persian) for the screening of depression in students. 2520 46

Background: Once-daily treatment formulation is associated with better adherence in comparison to more complex medication regimens. The study aimed to detect the extent of adherence to pharmacotherapy in Parkinson disease (PD) patients who take a minimum of three daily doses of drugs, and to identify factors associated with lower levels of adherence. Methods: The cohort was selected from non-demented PD patients. The 8-Item Morisky Medication Adherence Scale (MMAS-8), 8-Item Parkinson's Disease Questionnaire (PDQ-8), Geriatric Depression Scale (GDS), Non-Motor Symptom Assessment Scale (NMSS), 9-Item Wearing-off Questionnaire (WOQ-9), MDS-UPDRS III (motor examination), and IV (motor complications) scales were used in this study. Results: From a total of 124 subjects, 33.9% reported a high level of adherence, 29.8% reported a medium level of adherence, and 36.3% reported a low level of adherence to their pharmacotherapy. The level of non-adherence correlated with gender, longer disease duration, higher scores of PDQ-8, NMSS, WOQ-9, and MDS-UPDRS IV. Detailed analysis of NMSS demonstrated a correlation between the level of adherence and domains sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, and urinary symptoms. Independent risk factors for non-adherence were excessive daytime sleepiness, anhedonia, and forgetfulness. Conclusion: Non-adherence to more complicated medication regimens is frequent in PD patients and is associated with gender, longer PD duration, poorer quality of life, frequency and severity of non-motor symptoms, and more severe motor and non-motor fluctuations. Non-adherence was predicted by non-motor symptoms including fatigue, mood disturbances, and subjective cognitive complaints.
 ...
PMID:Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication. 3141 84